What is PLX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.22B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PLX?

P/E (TTM) is 11.82 and 52-week range is $1.60 to $3.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PLX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PLX?

The company profile lists revenue (TTM) near $79M, net income (TTM) near $18M, EPS (TTM) near $0.23 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Protalix Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Hackensack, New Jersey, US, 80.6M shares outstanding, ISIN US74365A3095 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Protalix Biotherapeutics Inc

$PLX

Health Care · Biotechnology

IR Run Scenarios

$2.78

+2.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 226 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Employees

226

Website

protalix.com/

IPO

2010-09-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)